Table 4.

The effect of lung transplantation on HRQL by age group

		Early change	Test of trend
SF12-PCS (MCID = 5)	18–49	17.7 (14.8, 20.6)	P=0.05
	50–64	14.3 (11.8, 16.7)
	65+	13.4 (10.0, 16.7)
SF12-MCS (MCID = 5)	18–49	6.4 (3.9, 8.8)	P=0.002
	50–64	6.5 (4.3, 8.6)
	65+	0.2 (−2.8, 3.3)
AQ20-R (MCID = 1.75)	18–49	8.3 (7.3, 9.2)	P=0.122
	50–64	8.2 (7.4, 9.0)
	65+	7.1 (6.1, 8.1)
EQ5D (MCID = 0.06)	18–49	0.20 (0.15, 0.25)	P=0.124
	50–64	0.17 (0.13, 0.21)
	65+	0.14 (0.09, 0.19)
EQVAS (MCID = 10)	18–49	33.2 (27.6, 38.9)	P=0.174
	50–64	30.8 (26.7, 34.9)
	65+	27.2 (21.5, 33.0)

For age group 18 – 49, n = 56; 50–64, n = 103; n = 52. Adjusted for sex, diagnosis, baseline body mass index, forced expiratory volume in 1 second, six minute walk distance and Lung Allocation Score

Early: Average change from before to 3 months after transplant. Effect estimates reflect average change in HRQL over the early or late time period.

COPD = Chronic Obstructive Pulmonary Disease; PAH = Pulmonary Arterial Hypertension; CF = Cystic Fibrosis; PF = Pulmonary Fibrosis; BMI = Body Mass Index; 6MWD = six-minute walk distance; FEV1 = forced expiratory capacity in 1 second; LAS = Lung Allocation Score; SF12-PCS = Medical Outcomes Study Short Form 12 Physical Component Summary scale; SF12-MCS = Medical Outcomes Study Short Form 12 Mental Component Summary scale; AQ20-R = Airway Questionnaire 20- Revised; score reversed for ease of interpretation); EQ5D = Euroqol 5D; EQVAS = Euroqol Visual Analog Scale